Search

Your search keyword '"Yokozeki, Hiroo"' showing total 1,050 results
Start Over Author "Yokozeki, Hiroo"
1,050 results on '"Yokozeki, Hiroo"'

4. Genome-wide association study reveals an association between the HLA-DPB1∗02:01:02 allele and wheat-dependent exercise-induced anaphylaxis

Author

Fukunaga, Koya, Chinuki, Yuko, Hamada, Yuto, Fukutomi, Yuma, Sugiyama, Akiko, Kishikawa, Reiko, Fukunaga, Atsushi, Oda, Yoshiko, Ugajin, Tsukasa, Yokozeki, Hiroo, Harada, Naoe, Suehiro, Masataka, Hide, Michihiro, Nakagawa, Yukinobu, Noguchi, Emiko, Nakamura, Masashi, Matsunaga, Kayoko, Yagami, Akiko, Morita, Eishin, and Mushiroda, Taisei

Published
2021
Full Text
View/download PDF

6. Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.

Author

Yokozeki, Hiroo, Murota, Hiroyuki, Matsumura, Takayo, Komazaki, Hiroshi, and Group, for the Nemolizumab-JP11 Study

Subjects
*ITCHING, *SLEEP quality, *PRURIGO, *TREATMENT effectiveness, *CORTICOSTEROIDS, *QUALITY of life
Abstract

Background Prurigo nodularis (PN), a chronic inflammatory skin condition, adversely affects the quality of life of affected individuals. Current treatment options for PN in Japan are limited. Objectives To evaluate the optimal dose, efficacy and safety of long-term treatment with nemolizumab in patients with PN in Japan. Methods In a 16-week double-blind phase II/III study, patients aged ≥ 13 years with PN were randomly assigned (1 : 1 : 1) to nemolizumab 30-mg, 60-mg or placebo groups, with concomitant topical corticosteroids, every 4 weeks. The primary efficacy endpoint was the percentage change in the weekly mean Peak Pruritus Numerical Rating Scale (PP-NRS) score (range 0–10, with higher scores indicating worse itching) from baseline to week 16. Secondary efficacy endpoints assessed the impact of treatment on pruritus, PN severity, sleep and quality of life. Results At week 16, the least-squares mean percentage change from baseline in the PP-NRS score was −61.1% in the nemolizumab 30-mg group (n = 77), −56.0% in the 60-mg group (n = 76), and −18.6% in the placebo group (n = 76). Differences between both nemolizumab groups and placebo were significant; the difference between the 30-mg and placebo groups was −42.5% [95% confidence interval (CI) −51.9 to −33.1; P < 0.0001], and between the 60-mg and placebo groups was −37.4% (95% CI −46.7 to −28.1; P < 0.0001). Patients treated with nemolizumab also had greater improvements in the number and severity of prurigo nodules, and in sleep and quality of life compared with the placebo group. Both nemolizumab doses were well tolerated. Conclusions Improvements in PN were greater following nemolizumab treatment, despite continuation of topical corticosteroids in both groups. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Japanese guidelines for occupational allergic diseases 2020

Author

Kunio Dobashi, Akiyama, Kazuo, Usami, Atsushi, Yokozeki, Hiroo, Ikezawa, Zenro, Tsurikisawa, Naomi, Nakamura, Yoichi, Sato, Kazuhiro, Okumura, Jiro, Takayama, Kaoru, Adachi, Mitsuru, Matsunaga, Kayoko, Naito, Kensei, Nakazawa, Tsugio, Ohta, Ken, Okano, Mitsuhiro, Tohda, Yuji, Watanabe, Masanari, Yamaguchi, Masao, and Dobashi, Kunio

Published
2020
Full Text
View/download PDF

12. Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial

Author

Wataya-Kaneda, Mari, Nagai, Hiroshi, Ohno, Yuuki, Yokozeki, Hiroo, Fujita, Yasuyuki, Niizeki, Hironori, Yoshida, Kazue, Ogai, Masaaki, Yoshida, Yuichi, Asahina, Akihiko, Fukai, Kazuyoshi, Tateishi, Chiharu, Hamada, Izumi, Takahata, Tatsuro, Shimizu, Kenji, Shimasaki, Shigeki, and Murota, Hiroyuki

Published
2020
Full Text
View/download PDF

17. Activated Akt expression is associated with the recurrence of primary melanomas and further refines the prognostic and predictive values for relapse in acral melanomas

Author

Nojima, Kohei, primary, Hayashi, Masahiro, additional, Tanemura, Atsushi, additional, Al‐Busani, Hind, additional, Saito, Toru, additional, Suzuki, Tamio, additional, Ishikawa, Masashi, additional, Mori, Taisuke, additional, Wada, Shogo, additional, Yamazaki, Naoya, additional, Katayama, Ichiro, additional, Mori, Hiroki, additional, Yokozeki, Hiroo, additional, Okiyama, Naoko, additional, Sasaki, Yoshiyuki, additional, and Namiki, Takeshi, additional

Published
2023
Full Text
View/download PDF

20. Activated Akt expression is associated with the recurrence of primary melanomas and further refines the prognostic and predictive values for relapse in acral melanomas.

Author

Nojima, Kohei, Hayashi, Masahiro, Tanemura, Atsushi, Al‐Busani, Hind, Saito, Toru, Suzuki, Tamio, Ishikawa, Masashi, Mori, Taisuke, Wada, Shogo, Yamazaki, Naoya, Katayama, Ichiro, Mori, Hiroki, Yokozeki, Hiroo, Okiyama, Naoko, Sasaki, Yoshiyuki, and Namiki, Takeshi

Subjects
PROGNOSIS, MELANOMA, DISEASE relapse, PROGRESSION-free survival, BRAF genes, OVERALL survival, PROGNOSTIC tests
Abstract

A PTEN deficiency leads to the activation of phospho‐Akt at serine 473 (p‐Akt) and promotes the tumorigenesis of melanomas by coupling with NUAK2 amplification. We tested the prognostic impact of p‐Akt and/or NUAK2 expression on the relapse‐free survival (RFS) and overall survival (OS) of melanoma patients. Primary tumors from patients with acral melanomas (112), Low‐cumulative sun damage (CSD) melanomas (38), and High‐CSD melanomas (18) were examined using immunohistochemistry and their prognostic significance was analyzed statistically. The expression of p‐Akt was found in 32.1%, 68.4%, and 55.6% of acral, Low‐CSD, and High‐CSD melanomas, while NUAK2 expression was found in 46.4%, 76.3%, and 50.0%, respectively. Either p‐Akt or NUAK2 expression was inversely correlated with the RFS of primary melanoma patients and acral melanoma patients (p‐Akt: p <.0001, p <.0001; NUAK2; p =.0005, p <.0001, respectively). Strikingly, multivariate analyses revealed that p‐Akt had a significant impact on RFS (Hazard ratio = 4.454; p <.0001), while NUAK2 did not. Further subset analyses revealed that p‐Akt expression had an inferior RFS of patients with acral melanomas (Hazard ratio = 4.036; p =.0005). We conclude that the expression of p‐Akt has a significant impact on RFS of patients with primary melanomas and can predict the relapse of patients with acral melanomas. Research Highlights: The expression of p‐Akt has a significant impact on relapse‐free survival in primary melanoma patients and can predict the relapse of acral melanoma patients. The expression of p‐Akt can be a promising biomarker to stratify acral melanomas for clinical trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Cutaneous basophil infiltration in atopic dermatitis is associated with abundant epidermal infiltration of helper T cells: A preliminary retrospective study.

Author

Nagashima, Natsumi, Ugajin, Tsukasa, Miyake, Kensuke, Walls, Andrew F., Namiki, Takeshi, Yokozeki, Hiroo, Karasuyama, Hajime, and Okiyama, Naoko

Abstract

Atopic dermatitis (AD) is a heterogenous inflammatory skin disorder. Our previous study revealed that basophil infiltration in skin is observed in approximately 60% of AD cases. However, the clinical and histological characteristics of AD associated with basophil infiltration remain unclear. We examined basophil infiltration by immunohistochemical staining of 38 specimens from 34 patients who underwent skin biopsies to diagnose AD from April 2016 to September 2021 at Tokyo Medical and Dental University Hospital. The patients/specimens were divided into two groups, 17 patients/21 specimens associated with little or no basophil infiltration (basophil‐low group) and 17 patients/17 specimens associated with marked basophil infiltration (basophil‐high group). The clinical characteristics of the patients (age, sex, complications, blood biomarkers, skin symptoms, and treatment) and histological features of the specimens were compared between the groups. Basophil‐high patients were significantly younger than basophil‐low patients. Blood basophil counts were higher in basophil‐high patients than in basophil‐low patients. CD4+ T‐cell infiltration was more marked in basophil‐high specimens than in basophil‐low specimens. CD4+ T cells infiltrated into the dermis as well as into the epidermis only in the basophil‐high specimens. Thus, basophil‐high AD can be characterized by skin lesions associated with abundant helper T‐cell infiltration in younger patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Supplementary Figure Legend from NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation

Author

Namiki, Takeshi, primary, Yaguchi, Tomonori, primary, Nakamura, Kenta, primary, Valencia, Julio C., primary, Coelho, Sergio G., primary, Yin, Lanlan, primary, Kawaguchi, Masakazu, primary, Vieira, Wilfred D., primary, Kaneko, Yasuhiko, primary, Tanemura, Atsushi, primary, Katayama, Ichiro, primary, Yokozeki, Hiroo, primary, Kawakami, Yutaka, primary, and Hearing, Vincent J., primary

Published
2023
Full Text
View/download PDF

25. Data from NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation

Author

Namiki, Takeshi, primary, Yaguchi, Tomonori, primary, Nakamura, Kenta, primary, Valencia, Julio C., primary, Coelho, Sergio G., primary, Yin, Lanlan, primary, Kawaguchi, Masakazu, primary, Vieira, Wilfred D., primary, Kaneko, Yasuhiko, primary, Tanemura, Atsushi, primary, Katayama, Ichiro, primary, Yokozeki, Hiroo, primary, Kawakami, Yutaka, primary, and Hearing, Vincent J., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figures S1-9 and Tables S1-3 from NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation

Author

Namiki, Takeshi, primary, Yaguchi, Tomonori, primary, Nakamura, Kenta, primary, Valencia, Julio C., primary, Coelho, Sergio G., primary, Yin, Lanlan, primary, Kawaguchi, Masakazu, primary, Vieira, Wilfred D., primary, Kaneko, Yasuhiko, primary, Tanemura, Atsushi, primary, Katayama, Ichiro, primary, Yokozeki, Hiroo, primary, Kawakami, Yutaka, primary, and Hearing, Vincent J., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results